Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
October 31, 2018 09:21 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting
October 09, 2018 08:30 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018
August 28, 2018 13:31 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress
August 14, 2018 16:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
June 27, 2018 07:05 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance
June 27, 2018 07:00 ET
|
Ritter Pharmaceuticals, Inc.
Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Highlights Key Phase 2b Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018
June 05, 2018 08:30 ET
|
Ritter Pharmaceuticals, Inc.
Additional Data Describes Novel Clinical Symptom Assessment Tool Developed in Phase 2b Trial and to be Used in Upcoming Phase 3 Clinical Trial LOS ANGELES, June 05, 2018 (GLOBE NEWSWIRE) -- Ritter...
Ritter Pharmaceuticals Announces Appointment of John W. Beck as Chief Financial Officer
May 29, 2018 06:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance
May 22, 2018 08:30 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...
Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates
May 15, 2018 16:10 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut...